Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.
Saved in:
| Title: | Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial. |
|---|---|
| Authors: | Gao Y; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Cheng AL; National Taiwan University Cancer Center, Taipei, Taiwan., Li LX; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Parent N; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Kichenadasse G; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.; Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia., Karapetis CS; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.; Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia., Rowland A; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Hopkins AM; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Sorich MJ; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia. |
| Source: | International journal of cancer [Int J Cancer] 2025 Jul 15; Vol. 157 (2), pp. 336-344. Date of Electronic Publication: 2025 Mar 13. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
